← Human Trials & Peer-Reviewed Studies
Effects of somatostatin prophylaxis after pylorus-preserving pancreaticoduodenectomy: increased delayed gastric emptying and reduced plasma motilin
Plain-language guide to PMID 16284796 (2005): randomized controlled trial study of Somatostatin, delayed gastric emptying on glp-1 medicines.
Key Facts
- PMID
- 16284796
- Journal
- World journal of surgery
- Year
- 2005
- Study type
- Randomized Controlled Trial
- Authors
- Shan YS et al. (6 authors)
- DOI
- 10.1007/s00268-005-7943-5
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Somatostatin in the context of delayed gastric emptying on glp-1 medicines and pancreatitis (after the acute phase), published as a randomized controlled trial.
The incidence of DGE, scintographic solid-phase emptying results on day 14 postoperatively, and sequential fasting plasma motilin levels were compared, as motilin levels are related to both gastric motility and somatostatin levels.
Who Took Part
The age groups tagged for this paper are adults, middle-aged adults, older adults and people over 80, both men and women.
From August 1997 to December 2000, a total of 23 post-PPPD patients were randomized to receive somatostatin prophylaxis [somatostain (+)] (n = 11) or not [somatostatin] (-) (n = 12).
How the Study Was Run
The researchers set it up as a randomized study.
The participants were allocated by chance, so the Somatostatin group and the comparison group should start out alike.
What Was Measured
The incidence of DGE, scintographic solid-phase emptying results on day 14 postoperatively, and sequential fasting plasma motilin levels were compared, as motilin levels are related to both gastric motility and somatostatin levels.
PubMed files the paper under topics including Chemoprevention, Gastric Emptying, Gastrointestinal Agents, Motilin, Pancreaticoduodenectomy and Somatostatin.
What This Means in Plain Language
The paper is a randomized study of Somatostatin in people with delayed gastric emptying on glp-1 medicines.
The publication is from 2005 (World journal of surgery), a journal based in United States.
More context: the Somatostatin compound page, Delayed gastric emptying on GLP-1 medicines research, Pancreatitis (after the acute phase) research.
Our Notes on the Compound
Somatostatin: A 14-amino-acid hormone that switches off the release of several other hormones, including growth hormone and insulin.
Related Pages
- Delayed gastric emptying on GLP-1 medicines research
- Pancreatitis (after the acute phase) research
- Somatostatin in the library
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.